Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment.

Dalekos GN, Wedemeyer H, Obermayer-Straub P, Kayser A, Barut A, Frank H, Manns MP.

J Hepatol. 1999 Mar;30(3):366-75.

PMID:
10190716
2.

A major CYP2D6 autoepitope in autoimmune hepatitis type 2 and chronic hepatitis C is a three-dimensional structure homologous to other cytochrome P450 autoantigens.

Sugimura T, Obermayer-Straub P, Kayser A, Braun S, Loges S, Alex B, Lüttig B, Johnson EF, Manns MP, Strassburg CP.

Autoimmunity. 2002 Dec;35(8):501-13.

PMID:
12765476
3.

Differences in anti-LKM-1 autoantibody immunoreactivity to CYP2D6 antigenic sites between hepatitis C virus-negative and -positive patients.

Kitazawa E, Igarashi T, Kawaguchi N, Matsushima H, Kawashima Y, Hankins RW, Miyakawa H.

J Autoimmun. 2001 Nov;17(3):243-9.

PMID:
11712862
4.

Detection of anti-LKM-1(anti-CYP2D6) by an enzyme-linked immunosorbent assay in adult patients with chronic liver diseases.

Miyakawa H, Kikazawa E, Abe K, Kikuchi K, Fujikawa H, Matsushita M, Kawaguchi N, Morizane T, Ohya K, Kako M.

Autoimmunity. 1999;30(2):107-14.

PMID:
10435724
5.

Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection.

Ma Y, Peakman M, Lobo-Yeo A, Wen L, Lenzi M, Gäken J, Farzaneh F, Mieli-Vergani G, Bianchi FB, Vergani D.

Clin Exp Immunol. 1994 Jul;97(1):94-9.

6.

Interferon therapy in LKM-1 positive patients with chronic hepatitis C: follow-up by a quantitative radioligand assay for CYP2D6 antibody detection.

Duclos-Vallée JC, Nishioka M, Hosomi N, Arima K, Leclercq A, Bach JF, Yamamoto AM.

J Hepatol. 1998 Jun;28(6):965-70.

PMID:
9672171
7.

Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease.

Kerkar N, Choudhuri K, Ma Y, Mahmoud A, Bogdanos DP, Muratori L, Bianchi F, Williams R, Mieli-Vergani G, Vergani D.

J Immunol. 2003 Feb 1;170(3):1481-9.

8.

Differences in antigenic sites, recognized by anti-liver-kidney microsome-1 (LKM-1) autoantibody, between HCV-positive and HCV-negative sera in Japanese patients.

Miyakawa H, Matsushima H, Narita Y, Hankins RW, Kitazawa E, Fujikawa H, Kikuchi K, Matsushita M, Abe K, Kawaguchi N, Morizane T, Kako M.

J Gastroenterol. 1998 Aug;33(4):529-35.

PMID:
9719237
9.

Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection.

Betterle C, Fabris P, Zanchetta R, Pedini B, Tositti G, Bosi E, de Lalla F.

Diabetes Care. 2000 Aug;23(8):1177-81.

10.

Sera of children with hepatitis C infection and anti-liver-kidney microsome-1 antibodies recognize different CYP2D6 epitopes than adults with LKM+/HCV+ sera.

Herzog D, Yamamoto AM, Jara P, Maggiore G, Sarles J, Alvarez F.

J Pediatr Gastroenterol Nutr. 1999 Nov;29(5):551-5.

PMID:
10554122
11.

Effect of interferon therapy on Japanese chronic hepatitis C virus patients with anti-liver/kidney microsome autoantibody type 1.

Iijima Y, Kato T, Miyakawa H, Ogino M, Mizuno M, Sugihara K, Ando T, Fujiwara K, Orito E, Ueda R, Mizokami M.

J Gastroenterol Hepatol. 2001 Jul;16(7):782-8.

PMID:
11446887
13.
14.

A new epitope of CYP2D6 recognized by liver kidney microsomal autoantibody from japanese patients with autoimmune hepatitis.

Imaoka S, Obata N, Hiroi T, Osada-Oka M, Hara R, Nishiguchi S, Funae Y.

Biol Pharm Bull. 2005 Dec;28(12):2240-3.

15.
16.

Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview.

Dalekos GN, Zachou K, Liaskos C, Gatselis N.

Eur J Intern Med. 2002 Aug;13(5):293-303.

PMID:
12144908
18.

[Serum autoantibodies of patients with chronic hepatitis C and the significance thereof in infection of hepatitis C virus].

Wu CH, Xu XY, Tian GS, Yu YY.

Zhonghua Yi Xue Za Zhi. 2006 Feb 14;86(6):390-3. Chinese.

PMID:
16677548
19.

Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes.

Todros L, Saracco G, Durazzo M, Abate ML, Touscoz G, Scaglione L, Verme G, Rizzetto M.

Hepatology. 1995 Nov;22(5):1374-8.

PMID:
7590650
20.

Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model.

Hintermann E, Holdener M, Bayer M, Loges S, Pfeilschifter JM, Granier C, Manns MP, Christen U.

J Autoimmun. 2011 Nov;37(3):242-53. doi: 10.1016/j.jaut.2011.06.005. Epub 2011 Jul 26.

PMID:
21795021

Supplemental Content

Support Center